Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study

BACKGROUND: Hypomethylating agents (HMA) are considered the first-line therapy for high-risk myelodysplastic syndromes (MDS). However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs. decitabine (DAC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Naibo, Qin, Tiejun, Du, Xiaoyan, Wang, Bingyi, Wang, Xiaoyun, Xu, Zefeng, Pan, Lijuan, Qu, Shiqiang, Xiao, Zhijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856837/
https://www.ncbi.nlm.nih.gov/pubmed/33514682
http://dx.doi.org/10.12659/MSM.928454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856837/
https://www.ncbi.nlm.nih.gov/pubmed/33514682
http://dx.doi.org/10.12659/MSM.928454

Ejemplares similares